TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24837444

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 407

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Duloxetine plus Gabapentin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Duloxetine vs. Pregabalin
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Duloxetine vs. Duloxetine plus Gabapentin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Pregabalin vs. Duloxetine and Duloxetine plus Gabapentin
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Duloxetine plus Gabapentin vs. Pregabalin
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Weight change among treatment groups
Number of subjects: 407
Study: 22592504

Group type: EXPERIMENTAL
Intervention: St John's wort (SJW) 900-1500 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 19891698

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Subdermal testosterone implants (TI)
Number of subjects: 38
Study: 22884063

Group type: EXPERIMENTAL
Intervention: 100 mg/d oral progesterone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 200 mg/d oral progesterone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 300 mg/d oral progesterone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 400 mg/d oral progesterone
Number of subjects: 80
Study: 15984008

Group type: EXPERIMENTAL
Intervention: Levodopa (100mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12822089

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (group B)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Magnification endoscopy (group C)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional endoscopy (group A)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Targeted biopsies after intravital staining
Number of subjects: 118
Study: 9801526

Group type: EXPERIMENTAL
Intervention: Recorded, preferred music played during bathing episodes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no music) condition
Number of subjects: 18
Study: 8549849

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low sodium diet (good compliance)
Number of subjects: 0
Study: 2672062

Group type: EXPERIMENTAL
Intervention: Bright light therapy at high intensity (2000 lux)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bright light therapy at low intensity (300 lux)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 805354

Group type: EXPERIMENTAL
Intervention: Bendigon
Number of subjects: 28
Study: 31808295

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 802
Study: 30859660

Group type: EXPERIMENTAL
Intervention: Turmeric (2,100 mg powdered rhizome of turmeric daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28683750

Group type: EXPERIMENTAL
Intervention: mRDTs intervention arm
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2400
Study: 25120022

Group type: EXPERIMENTAL
Intervention: 0.5x ED95 rocuronium bromide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1x ED95 rocuronium bromide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.5x ED95 rocuronium bromide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2x ED95 rocuronium bromide
Number of subjects: 100

Group type: COMPARATOR
Intervention: No rocuronium bromide (Control group)
Number of subjects: 100
Study: 22961992

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Distraction strategy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Spontaneous strategies
Number of subjects: 3
Study: 21042901

Group type: EXPERIMENTAL
Intervention: SLIPA™
Number of subjects: 101

Group type: COMPARATOR
Intervention: LMA‐ProSeal™
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: SLIPA™ and LMA‐ProSeal™
Number of subjects: 101
Study: 18793923

Group type: EXPERIMENTAL
Intervention: epoxy resin-based sealer (plus gutta-percha)
Number of subjects: 22

Group type: COMPARATOR
Intervention: untreated canal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: epoxy resin infiltration
Number of subjects: 22
Study: 16582864

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g, single dose 30 min before surgery)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Cefazolin (2 g, single dose 30 min before surgery)
Number of subjects: 698
Study: 12837854

Group type: EXPERIMENTAL
Intervention: CP-346086 (10 mg/kg/day) for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP-346086 (single oral dose of 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP-346086 (single oral dose of 1.3 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CP-346086 (30 mg/day for 2 weeks)
Number of subjects: 0
Study: 10755457

Group type: EXPERIMENTAL
Intervention: Infant formula milk supplemented with 0.35% DHA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Infant formula milk supplemented with 0.36% DHA and 0.72% arachidonic acid (AA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control formula (no DHA or AA)
Number of subjects: 56
Study: 8621785

Group type: EXPERIMENTAL
Intervention: L-arginine (7 grams x 3/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 27
Study: 1413587

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: UHF therapy
Number of subjects: 78
Study: 3890140

Group type: EXPERIMENTAL
Intervention: Atropine (not specified dosage or duration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: GIP infusion without atropine
Number of subjects: 8
Study: 31915366

Group type: EXPERIMENTAL
Intervention: venetoclax + hypomethylating agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: glasdegib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ivosidenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: midostaurin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin (GO)
Number of subjects: 0
Study: 29694236

Group type: EXPERIMENTAL
Intervention: Video-assisted teaching
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine teaching
Number of subjects: 28
Study: 26117584

Group type: EXPERIMENTAL
Intervention: Self-defined attractive body parts exposure
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Self-defined unattractive body parts exposure
Number of subjects: 22
Study: 24952868

Group type: EXPERIMENTAL
Intervention: Nocturnal heart rate pattern 3 (nondipping)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Nocturnal heart rate patterns 2 and 3
Number of subjects: 492
Study: 23106927

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 129
Study: 20204353

Group type: EXPERIMENTAL
Intervention: Histological evaluation of bone fragments obtained during radiofrequency ablation (RFA)
Number of subjects: 39
Study: 18315507

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg three times a day for 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15966876

Group type: EXPERIMENTAL
Intervention: Active laser treatment with wavelengths of 635 and 830 nm
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 12198695

Group type: EXPERIMENTAL
Intervention: Duodenal perfusion of lipids at 1 kcal/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Duodenal perfusion of lipids at 0 kcal/min (saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duodenal perfusion of lipids at 0.5 kcal/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gas plus lipids challenge test
Number of subjects: 30
Study: 10202870

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 38

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 38

Group type: COMPARATOR
Intervention: IVF vs ICSI
Number of subjects: 38
Study: 7758260

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 U at 0 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (120 U at 0 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 U at 0 and +20 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (120 U at +20 min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Post‐prandial intravenous insulin
Number of subjects: 17
Study: 2083922

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (20 mg infused intravenously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 227180

Group type: EXPERIMENTAL
Intervention: 1 gm. l‐tryptophan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3 gms. l‐tryptophan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30153085

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution
Number of subjects: 1005
Study: 28504988

Group type: EXPERIMENTAL
Intervention: Epidural catheter placement at L4-5 interspace
Number of subjects: 148

Group type: COMPARATOR
Intervention: Epidural catheter placement at L1-2 interspace
Number of subjects: 148
Study: 26895846

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397
Study: 25225008

Group type: EXPERIMENTAL
Intervention: Creighton Model FertilityCare System (CrMS) instruction
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group advice to have intercourse 2‐3 times per week
Number of subjects: 143
Study: 21805606

Group type: EXPERIMENTAL
Intervention: Nobori biolimus A9-eluting stent
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cypher sirolimus-eluting stent
Number of subjects: 335
Study: 19386792

Group type: EXPERIMENTAL
Intervention: Exogenous PTH administered subcutaneously to male Sprague-Dawley rats
Number of subjects: 0
Study: 17244215

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Timolol‐dorzolamide combination twice daily
Number of subjects: 65
Study: 15821205

Group type: EXPERIMENTAL
Intervention: IV clindamycin
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV ampicillin/sulbactam (normal dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV ampicillin/sulbactam (half dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV panipenem/betamiprom
Number of subjects: 100
Study: 11997277

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 897

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 897
Study: 9219402

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg daily for 5 days
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Penicillin V 250 mg four times a day for 5 days
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 7715474

Group type: EXPERIMENTAL
Intervention: 1.5 mg/day percutaneous 17 beta‐oestradiol (E2) for 36 months
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day oral conjugated oestrogens (CEE) for 24 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Untreated group (control) for 24 months
Number of subjects: 68
Study: 3503665

Group type: EXPERIMENTAL
Intervention: High tones (target tones)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nontarget tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preceding sequence of tones
Number of subjects: 0
Study: 31038645

Group type: EXPERIMENTAL
Intervention: Informative material on organ donation
Number of subjects: 739

Group type: COMPARATOR
Intervention: Control group (no informative material)
Number of subjects: 739
Study: 29589480

Group type: EXPERIMENTAL
Intervention: Passive range of motion in ankle dorsiflexion with flexed and extended knee
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gait Variable Score of the ankle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peak dorsiflexion during gait
Number of subjects: 60
Study: 27442662

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 75°C
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiofrequency thermocoagulation at 68°C
Number of subjects: 62
Study: 23478748

Group type: EXPERIMENTAL
Intervention: ω-3 PUFA supplementation (1.2 g per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ω-3 PUFA supplementation
Number of subjects: 81
Study: 22614774

Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate (LO) 20 or 40 mg (depending on age), single inhalation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Zanamivir (ZN) 20 mg, inhaled twice daily for 5 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate (LO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Zanamivir (ZN)
Number of subjects: 112
Study: 19610037

Group type: EXPERIMENTAL
Intervention: Herbal therapy treatment (PT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical antibiotic treatment (C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of PT group vs C group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Herbal preparations
Number of subjects: 32
Study: 19064472

Group type: EXPERIMENTAL
Intervention: Active intervention (four 2‐hour manualized educational/support group meetings; n = 31)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Written materials only (n = 23)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (written materials after a posttest; n = 12)
Number of subjects: 66
Study: 15936869

Group type: EXPERIMENTAL
Intervention: Darifenacin immediate release (IR) 2.5 mg t.i.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg t.i.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Darifenacin controlled release (CR) 15 mg q.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg t.i.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Darifenacin CR 30 mg q.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Darifenacin CR (both doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oxybutynin (both doses)
Number of subjects: 65
Study: 15229420

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection (1:10,000 solution, mean volume 18.0 mL)
Number of subjects: 34
Study: 10743448

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.15 mg followed by fentanyl 0.05 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Morphine 15 mg followed by morphine 7 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Remifentanil and isoflurane
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol
Number of subjects: 551
Study: 9384339

Group type: EXPERIMENTAL
Intervention: Pnc-T
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pnc-D
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pnc-T and Pnc-D
Number of subjects: 75
Study: 8386997

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium chloride (n = 20)
Number of subjects: 40
Study: 3884411

Group type: EXPERIMENTAL
Intervention: Buflomedil hydrochloride
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dihydrogenated ergot alkaloids
Number of subjects: 76
Study: 3286064

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nocturnal sleep
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fasting insulin concentration
Number of subjects: 17
Study: 30321319

Group type: EXPERIMENTAL
Intervention: VFR-CV (vacuum‐formed thermoplastic retainers constructed on stone models)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VFR-3D (vacuum‐formed thermoplastic retainers constructed on 3D printed models)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not explicitly defined, but implied as the other intervention in crossover)
Number of subjects: 30
Study: 28397155

Group type: EXPERIMENTAL
Intervention: Good School Toolkit
Number of subjects: 42
Study: 26265498

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Number of subjects: 2
Study: 23577218

Group type: EXPERIMENTAL
Intervention: Cognitive training group (n=34)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Active control group (n=17)
Number of subjects: 51
Study: 21255780

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19151305

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound-guided posterior (subgluteal) approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior approach to sciatic nerve block
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both approaches to sciatic nerve block
Number of subjects: 100
Study: 16512755

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish administration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 26
Study: 15309486

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with 0.02% mitomycin C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trabeculectomy with 0.02% mitomycin C
Number of subjects: 22
Study: 11545549

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Indinavir and Ritonavir
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NRTI-NNRTI
Number of subjects: 200
Study: 9311951

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60,000 microg retinol equivalents)
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in xerophthalmic children (n = 86)
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in initially wasted children (n = 34)
Number of subjects: 3377

Group type: COMPARATOR
Intervention: Placebo-control (300 RE)
Number of subjects: 3377
Study: 8365423

Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 3773023

Group type: EXPERIMENTAL
Intervention: Intravenous solution (IV) only
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oral rehydration along with intravenous solution (ORS/IV)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 29575009

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 26669642

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 25392971

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (2W, 200mJ pulse energy, 10pps)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 20
Study: 23265585

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502
Study: 20728874

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sleep therapy
Number of subjects: 30
Study: 18005970

Group type: EXPERIMENTAL
Intervention: Laboratory sessions and intensive clinical tutorials
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine tutoring (control group)
Number of subjects: 144
Study: 15717256

Group type: EXPERIMENTAL
Intervention: Once-daily emtricitabine, didanosine, and efavirenz (n=178)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Protease inhibitor (PI) based regimen (n=177)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Once-daily emtricitabine, didanosine, and efavirenz
Number of subjects: 355
Study: 12860502

Group type: EXPERIMENTAL
Intervention: Linezolid (i.v. 600 mg BID for 7-28 days or switched to oral 600 mg BID)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Teicoplanin (i.v. alone or switched to i.m. administration)
Number of subjects: 203
Study: 10493326

Group type: EXPERIMENTAL
Intervention: Integrated outpatient treatment (IOT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard alcoholism treatment)
Number of subjects: 105
Study: 7563531

Group type: EXPERIMENTAL
Intervention: Social skills intervention (5 sessions)
Number of subjects: 128

Group type: COMPARATOR
Intervention: HIV education condition (1 session)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Delayed HIV education control (no information until follow-up)
Number of subjects: 128
Study: 1836425

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg/4 weeks s.c., n = 20)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Danazol (2 x 400 mg/day p.o., n = 13)
Number of subjects: 33
Study: 7042355

Group type: EXPERIMENTAL
Intervention: Indoprofen 300 mg/day
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg/day
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg/day
Number of subjects: 147
Study: 31680395

Group type: EXPERIMENTAL
Intervention: DLMR01 (polycaprolactone-based dermal filler)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RJR (purified polynucleotide dermal filler)
Number of subjects: 30
Study: 29299741

Group type: EXPERIMENTAL
Intervention: ILM peeling (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No ILM peeling (Group B)
Number of subjects: 43